Business Blockbuster - Helpng business to be more visible on Google

Business Daily Media


.

AIM Vaccine mRNA RSV Vaccine Submits for Clinical Trials in the U.S.

Multiple Institutions Give AIM a "Buy" Rating

HONG KONG SAR - Media OutReach Newswire – 5 February 2025 - AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to the U.S.

Food and Drug Administration (FDA). The vaccine has demonstrated significantly higher humoral and cellular immunity compared to internationally marketed products. If the product progresses smoothly, it will accelerate AIM Vaccine's international expansion and contribute to substantial performance growth.

In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly higher levels of specific IgG antibody titers, live-virus neutralizing antibody potency, and specific T-cell immunity compared to internationally marketed mRNA RSV control vaccines.

This announcement highlights AIM Vaccine's innovative capabilities and underscores the acceleration of its internationalization efforts, which have been recognized by multiple institutions.

Recently, FOSUN INTERNATIONAL SECURITIES initiated coverage of AIM Vaccine, assigning a "Buy" rating with a 12-month target price of HKD 11.0. The report cited the company's strong product pipeline, technological leadership, and potential for international growth as key factors. Similarly, SDICSI released a research report predicting that AIM Vaccine will launch 1-2 products annually over the next three years. If the products in development gain approval and progress smoothly in international markets, they are expected to drive new performance growth and expand market potential. SDICSI also assigned a "Buy" rating with a target price of HKD 9.5.

FOSUN INTERNATIONAL SECURITIES's analysis indicates that the Chinese vaccine market is evolving in line with global trends, where high-value products and leading companies dominate. With its differentiated advantages, AIM Vaccine is poised to secure a leading position in the domestic market while achieving scalable expansion internationally. Additionally, the company's comprehensive and iterative product portfolio is expected to enhance its market share, pricing power, and profitability, further supporting long-term growth.

The report also emphasized that AIM Vaccine, with its diversified product portfolio, technological strengths, and global expansion strategy, presents an attractive investment opportunity for investors. With a series of high-value products set to launch and profitability expected to rebound from 2025 onwards, the company is positioned for strong growth and potential valuation reassessment.

Globally, there are currently no approved antiviral drugs for RSV available for clinical use. Vaccination for active immune prophylaxis remains the most effective means to prevent severe RSV infections. No RSV vaccines have been approved for marketing in PRC. In 2023, global sales of RSV vaccines reached USD 2.46 billion, and according to industry consultants, the market size is expected to grow to approximately USD 16.7 billion by 2030.

The mRNA vaccine field is still wide open with plenty of opportunities, as there are few competitors globally. AIM Vaccine is one of the earliest companies in PRC to develop mRNA vaccine products and is among the first domestic vaccine enterprises to obtain independent patents for mRNA technology. The company has established a mature mRNA vaccine R&D system and has developed multiple mRNA candidate vaccines, including vaccines for shingles, rabies, and influenza, in addition to the mRNA RSV vaccine.
Hashtag: #AIMVaccine

The issuer is solely responsible for the content of this announcement.

News from Asia

Allianz: Reported AI losses understate the true risk and are only the tip of the iceberg

Allianz Commercial analysis highlights emerging and interconnected risks and claims scenarios related to global AI adoption in businesses.

APEC Gathering Fulfills Shenzhen Vendor’s 25-Year Global Friendship Wish

SHENZHEN, CHINA — Media OutReach Newswire – 19 November 2026 – Amid the ongoing 33rd APEC Economic Leaders' Meeting hosted in Shenzhen, a heartwarming story of cross-border friendship has emerged ...

Viet Nam Takes Global Lead in New Climate-Smart Agrifood Partnership Launched at COP31

ANTALYA, TURKEY– Media OutReach Newswire – 19 November 2026 – Viet Nam has taken a significant step in advancing its role in international climate and food systems diplomacy with the launch of a n...

SACOFA Fortifies Connectivity Partnership to Advance Kenyalang Smart City, witnessed by The Premier of Sarawak

SARAWAK, MALAYSIA – Media OutReach Newswire – 19 November 2026 – SACOFA Sdn Bhd (SACOFA) is strengthening its role as the primary backhaul connectivity and telecommunications infrastructure partne...

Dual Engines Driving the Green Transition! WGO Hosts the "Sustainable Finance Award" and "Sustainable Enterprise Award" to Honour Cross-Sector Pioneers

HONG KONG SAR – Media OutReach Newswire – 19 November 2026 – The World Green Organisation (WGO) proudly hosted the presentation ceremony for the "Sustainable Finance Award" and the "Sustainable En...

From the South China Sea to the Aegean: Nansha Seeks Closer Cooperation with Greece in Coastal Sports and Tourism

GUANGZHOU, CHINA – Media OutReach Newswire – 19 November 2026 – During the China-Greece Sports and Cultural Exchange Week held in Athens on November 3, a delegation from Nansha District, Guangzhou...

Yicura BioMed Holds Pre-Launch Preparation Meeting and IDMC Kick-off Meeting for ICVAX-201 Clinical Project

ICVAX® Phase II Clinical Study Enters Key Preparation StageBEIJING, CHINA – Media OutReach Newswire – 19 November 2026 – Yicura BioMed held the Pre-launch Preparation Meeting and the Independent D...

Advanced Robotics Conference 2026: FEV highlights pathways to industrial deployment of Physical AI

AACHEN, GERMANY – Newsaktuell – 19 November 2026 – The Advanced Robotics Conference (ARC) 2026 will bring together leading representatives from international technology companies, star...

LANDMARK’s ‘Destination CENTRAL’ Opens an Inspiring New Chapter for the Festive Season in Hong Kong

Heightening the Global Momentum of Louis Vuitton’s Monumental Façade and Welcoming the Arrival of “Christmas at The Gloucester Hotel”HONG KONG SAR – Media OutReach Newswire – 19 November 2026 –Thi...

AXS and PayerMax Advance Omnichannel Payment Acceptance for Merchants

SINGAPORE – Media OutReach Newswire – 19 November 2026 – AXS Pte Ltd (AXS), a leading bill management and payment acceptance solutions provider, and PayerMax, a global payment solutions provider, ...

New Research Highlights What Australian Retailers Need to Deliver

New research among Australian SHEIN customers reveals how price comparisons, product quality and customer reviews are shaping purcha...

Why the secrecy around car insurance?

Every year, millions of Australians receive their car insurance renewal and promise themselves they’ll look at it properly later. Then life gets in ...

Australian workers spend almost an hour a day administering email

Research finds email filing, searching and rework consuming an estimated 58 minutes a day and potentially exposing organisations to millionsAustralian...

Customer Service Is Becoming Part of the Small Business Sales and Marketing Engine

For Customer Service Week, 5-9 October, Thryv is urging small businesses to look beyond generating  enquiries and examine what happens after a custome...

Gift Cards as the gateway to agentic payments

Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...

Why Data Accumulation Without Governance Undermines Sustainability Goals

In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...